Quantcast

Latest Neuroprotection Stories

2010-06-24 09:00:00

FREMONT, Calif., June 24 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK: "QPI-1007, an ocular neuroprotective siRNA for ameliorating RGC (retinal ganglion cell) loss," presented by Elena Feinstein, Chief Scientific...

2010-05-24 08:00:00

JACKSONVILLE, Fla., May 24 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway...

fd660b6743ef885fe305aec3ed97d0a71
2010-05-17 11:05:26

Researchers explore potential benefits of caffeine in special supplement to the Journal of Alzheimer's Disease Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated. Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may be protective against the cognitive decline seen in dementia...

2010-05-11 09:26:00

LONDON, May 11, 2010 /PRNewswire/ -- The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain. The...

2010-04-23 10:44:00

NEW YORK, April 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced more than $3 million in previously unannounced awards ending the first quarter of 2010. The funded projects complement the Foundation's annually occurring Pipeline Programs and Critical Challenges in Parkinson's Disease initiatives, which aim to accelerate PD therapeutic development. Many of the 17 different projects announced today provide additional funding to advance...

2010-04-19 12:33:19

A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS). Transplanted OECs, known to retain exceptional plasticity and promote olfactory blood vessel growth while offering neuroprotection, have been demonstrated to be...

2010-04-16 13:50:45

Richard Borgens and his colleagues from the Center for Paralysis Research at the Purdue School of Veterinary Medicine have a strong record of inventing therapies for treating nerve damage. From Ampyra, which improves walking in multiple sclerosis patients to a spinal cord simulator for spinal injury victims, Borgens has had a hand in developing therapies that directly impact patients and their quality of life. Another therapy that is currently undergoing testing is the use of polyethylene...

2010-03-03 13:21:51

The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. This discovery was published by scientists of the German Cancer Research Center. In mice, the researchers found out that if they switch off CD95L, the injured spinal cord heals and the animals regain better ability to move. Therefore, substances which block the death messenger might offer a new approach in the treatment of severe...

2010-02-11 06:00:00

SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery. The French research team was led by Prof. Michel Lazdunski, world-renowned specialist of pharmacology. The data demonstrates...

2010-02-09 06:00:00

HERZLIYA PITUACH, Israel, February 9 /PRNewswire/ -- SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM). SMT R&D developed a novel technology for brain protection (Neuroprotection) from stroke complication hazards arising from invasive cardiology procedures and heart surgery. The rate of stroke and silent brain damage is the leading severe limiting factor for delivering...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related